Abstract
This article reviews the design of a recently published randomized controlled trial (RCT) on immediate vs delayed access to gender-affirming hormones for transgender and gender-diverse (TGD) people and outlines key learning points that clinicians should know about how RCTs can and cannot contribute to advancing health equity for TGD people.
| Original language | English (US) |
|---|---|
| Pages (from-to) | E684-E689 |
| Journal | AMA Journal of Ethics |
| Volume | 26 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 2024 |
ASJC Scopus subject areas
- Issues, ethics and legal aspects
- Health(social science)
- Health Policy
Fingerprint
Dive into the research topics of 'Roles of Randomized Controlled Trials in Establishing Evidence-Based Gender-Affirming Care and Advancing Health Equity'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS